Difference between revisions of "SUIT-005"
From Bioblast
Line 6: | Line 6: | ||
::: '''[[Categories of SUIT protocols |SUIT-category]]:''' FNS(Oct,PM) | ::: '''[[Categories of SUIT protocols |SUIT-category]]:''' FNS(Oct,PM) | ||
::: '''[[SUIT protocol pattern]]:''' orthogonal 1OctM;2D;3P;4S;5U;6Rot;7Ama | ::: '''[[SUIT protocol pattern]]:''' orthogonal 1OctM;2D;3P;4S;5U;6Rot;7Ama | ||
The SUIT-005 protocols provide information on the [[Fatty_acid_oxidation_pathway_control_state|F-pathway]], the combined [[FN|FN]] pathway, and convergent [[FNS |FNS]] pathways in the [[Oxidative phosphorylation|OXPHOS state]]. [[FNS |FNS]] comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum OXPHOS- and ET-capacity. SUIT-005 can be extended with the CIV assay module. | |||
__TOC__ | __TOC__ | ||
Communicated by [[Iglesias-Gonzalez J]], [[Gnaiger E]] (last update 2019-01-26) | Communicated by [[Iglesias-Gonzalez J]], [[Gnaiger E]] (last update 2019-01-26) |
Revision as of 14:29, 4 February 2019
Description
Abbreviation: FNS(Oct,PM)
Reference: A: short RP2 when malate-anaplerotic activity is zero »Versions
- SUIT-category: FNS(Oct,PM)
- SUIT protocol pattern: orthogonal 1OctM;2D;3P;4S;5U;6Rot;7Ama
The SUIT-005 protocols provide information on the F-pathway, the combined FN pathway, and convergent FNS pathways in the OXPHOS state. FNS comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum OXPHOS- and ET-capacity. SUIT-005 can be extended with the CIV assay module.
Communicated by Iglesias-Gonzalez J, Gnaiger E (last update 2019-01-26)
DLP applications
- SUIT-005 O2 pfi D011 for permeabilized fibers
References
Steps and respiratory states
Step | State | Pathway | Q-junction | Comment - Events (E) and Marks (M) |
---|---|---|---|---|
1OctM | OctML(n) | F(N) | FAO | 1OctM
|
2D | OctMP | F(N) | FAO | 1OCtM;2D
|
2c | OctMcP | F(N) | FAO | 1OCtM;2D;2c
|
3P | OctPMP | FN | F&CI | 1OctM;2D;2c;3P
|
4S | OctPMSP | FNS | F&CI&II | 1OctM;2D;2c;3P;4S
|
5U | OctPMSE | FNS | F&CI&II | 1OctM;2D;2c;3P;4S;5U
|
6Rot | SE | S | CII | 1OctM;2D;3P;4S;5U;6Rot
|
7Ama | ROX | 1OctM;2D;3P;4S;5U;6Rot;7Ama
|
Step | Respiratory state | Pathway control | ET-Complex | Comment |
---|---|---|---|---|
## AsTm | AsTmE | CIV | CIV | |
## Azd | CHB |
- Bioblast links: SUIT protocols - >>>>>>> - Click on [Expand] or [Collapse] - >>>>>>>
- Coupling control
- Pathway control
- Main fuel substrates
- » Glutamate, G
- » Glycerophosphate, Gp
- » Malate, M
- » Octanoylcarnitine, Oct
- » Pyruvate, P
- » Succinate, S
- Main fuel substrates
- Glossary
Strengths and limitations
- :::+ Reasonable duration of the experiment (1.5 to 2 h); 2-3 h when the CIV module is added.
- + The protocol provides information on F-OXPHOS capacity in the absence of a significant OXPHOS-capacity in the malate anaplerotic pathway control state.
- + FNS comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum OXPHOS- and ET-capacity.
- + PM & S reconsitutes TCA cycle activity (PMS) if the 2-oxoglutarate carrier does not outcompete the sources of 2-oxoglutarate.
- + Application of the cytochrome c test early in the protocol ensures comparability of all states in case of any effect of c.
- - F-OXPHOS capacity may be underestimated with Oct. In human heart muscle addition of Oct to palmitoylcarnitine (Pal) & malate increased OXPHOS-capacity by 26% (Lemuieux et al 2011).
- - SRotE may be underestimated if S is not saturating.
Compare SUIT protocols
- SUIT-002 check for malate-linked anaplerotic activity
MitoPedia concepts:
MiP concept,
SUIT protocol,
Recommended
MitoPedia methods:
Respirometry